EGFR and squamous cell lung carcinoma: A recent phase III trial in patients with squamous cell carcinoma of the lung and selected for EGFR overexpression but not for EGFR mutation revealed a significantly improved overall survival of 11.8 months in patients receiving the EGFR-mAb necitumumab plus gemcitabine-cisplatin versus 10 months in the gemcitabine-cisplatin control group [HR 0.79; 95% CI, 0.69- 0.92] [78].